SCI & TECH● ELEVATED3d ago · Oct 24, 2026, 5:45 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
newschannel9.com · United States · global
A personalized mRNA vaccine developed by Moderna and Merck has shown to reduce the risk of melanoma relapse in late-stage trials. This represents a potentially significant advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
BUSINESS4h ago21 years ago, Walmart pledged to protect one acre for every acre it developed: since then, the program has helped protect more than 2.2 million acres in the United StatesClarínPOLITICS20h agoMidterms in the United States: Abdul El-Sayed, Trump's bête noire who could swing the SenateLe Figaro InternationalWORLD1d agoF1: Antonelli two points from title after winning United States Grand PrixANSA [en]WORLD1d agoUnited States Grand Prix : Formula 1 Teams & Drivers report from COTAgrandprix247.com · Australia
More in Sci & Tech
SCI & TECH18m agoSantoli: We are nearing a now-or-never moment for the AI trade to reboundCNBCSCI & TECH46m agoGreenhouse gases reached a new record and warn about the impact El Niño will have.ClarínSCI & TECH52m agoDays will get way shorter in November: How much daylight we’ll loseThe HillSCI & TECH53m agoTo the moon and beyond: Astronauts Chris Hadfield and Victor Glover on why the 'New Space race mattersEuroNews [en]